C6022
赛庚啶 盐酸盐 倍半水合物
≥98% (TLC), solid
别名:
水合哌啶4-(5H-二苯并[a，d]环庚基-5-亚烷基)-1-甲基-盐酸盐 (2:3)
登录 查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H21N·HCl·1.5H2O
化学文摘社编号:
分子量:
350.88
EC 号:
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
质量水平
方案
≥98% (TLC)
表单
solid
颜色
white to slightly yellow
溶解性
ethanol: soluble
methanol: soluble
创始人
Merck & Co., Inc., Kenilworth, NJ, U.S.
SMILES字符串
Cl.CN1CCC(\CC1)=C2/c3ccccc3C=Cc4ccccc24
InChI
1S/2C21H21N.2ClH.3H2O/c2*1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21;;;;;/h2*2-11H,12-15H2,1H3;2*1H;3*1H2
InChI key
ZEAUHIZSRUAMQG-UHFFFAOYSA-N
基因信息
human ... HRH1(3269), HTR2A(3356), HTR2B(3357), HTR2C(3358)
正在寻找类似产品? 访问 产品对比指南
应用
盐酸赛庚啶倍半水合物已被用于：
降钙素基因相关肽（CGRP）的抑制
- 检测5-羟色胺受体（5-HT）诱导的炎症中的抗炎活性
- 螃蟹中体内和体外生物检测中5-HT的抑制
- 胚胎生理性实验中5-HT的抑制
降钙素基因相关肽（CGRP）的抑制
生化/生理作用
赛庚啶盐酸盐倍半水合物是一种血清素受体（5-HT2 / 5-HT1C）拮抗剂、H1组胺受体拮抗剂和止痒剂。赛庚啶对5-HT的抑制作用可改善精神分裂症的认知功能。赛庚啶对治疗功能性胃肠道疾病（FGID）有效。食品药品监督管理局（FDA）批准的赛庚啶具有抗抑郁和抗血小板功能。它可有效地治疗血栓栓塞性疾病。赛庚啶能够抑制赖氨酸甲基转移酶7/9（Set7/9），导致乳腺癌细胞中雌激素受体（ERα）的表达减少和生长停滞。
特点和优势
该化合物是由Merck & Co., Inc., Kenilworth, NJ, U.S.开发的。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单， 请单击此处。
警示用语：
Danger
危险分类
Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
靶器官
Respiratory system
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
个人防护装备
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
H W Suh et al.
Neuropeptides, 33(2), 121-129 (2000-02-05)
The present study was designed to investigate the modulatory effects of blockade of spinal histamine receptors on antinociception induced by supraspinally administered mu-epsilon-, delta-, and kappa-opioid receptor agonists. The effects of intrathecal (i.t.) injections with cyproheptadine [a histamine-1 (H1) receptor
Identification of cyproheptadine as an inhibitor of SET domain containing lysine methyltransferase 7/9 (Set7/9) that regulates estrogen-dependent transcription
Takemoto Y, et al.
Journal of Medicinal Chemistry, 59(8), 3650-3660 (2016)
Cyproheptadine: a potentially effective treatment for functional gastrointestinal disorders in children
Krasaelap A and Madani S
Pediatric Annals, 46(3), e120-e125 (2017)
E O Okoro
The Journal of pharmacy and pharmacology, 51(8), 953-957 (1999-09-30)
We have previously shown that elimination of buffer Ca2+ markedly reduced maximum 5-HT-induced contractions. We have now investigated the effect of L-type Ca2+-channel blockers and 5-HT2 receptor antagonists on 5-HT- and K+-induced contractions in rat aorta to explore the possibility
Effects of the 5HT antagonist cyproheptadine on neuropsychological function in chronic schizophrenia
Chaudhry IB, et al.
Schizophrenia Research, 53(1-2), 17-24 (2002)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持